M&A

Lilly to acquire Calytrix Bio in deal worth $1.5 billion betting on breakthrough MPN therapies

Calytrix Bi is developing precision, disease-modifying treatments for patients with myeloproliferative neoplasms

  • By IPP Bureau | November 19, 2026
Eli Lilly and Company is set to acquire biotechnology firm Calytrix Bio in a deal that could be worth up to $1.5 billion, including upfront and milestone-based payments.
 
This, as the pharmaceutical giant moves to advance a promising experimental therapy targeting rare blood cancers.
 
Calytrix Bi is developing precision, disease-modifying treatments for patients with myeloproliferative neoplasms (MPNs).
 
The deal puts the spotlight on Calytrix's lead investigational asset: a biparatopic antibody designed to target mutant calreticulin (mCALR), a key disease-driving mutation associated with essential thrombocythemia (ET) and myelofibrosis (MF).
 
Unlike existing drug therapies, which largely focus on controlling symptoms and managing complications, Calytrix's experimental approach aims to target the underlying cause of the disease. The antibody is designed to deliver broad activity against mutant CALR while selectively eliminating disease-driving cells and sparing healthy tissues and normal blood-cell production.
 
The company believes the therapy's potential safety and convenience profile could support earlier intervention and long-term treatment, addressing a significant unmet need among patients with mCALR-driven ET and MF.
 
"Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," said Brad Prosek, President and Chief Executive Officer of Calytrix Bio. 
 
"From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF. This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum. I am deeply grateful to our team, scientific advisors, and committed investors, each of whom has supported delivery of Calytrix's program to the starting line for clinical development."
 
Under the agreement, Lilly will acquire Calytrix, with the company's shareholders eligible to receive up to $1.5 billion in cash. The consideration includes an upfront payment and additional payments tied to the achievement of specified clinical and regulatory milestones.
 
The acquisition gives Lilly an opportunity to advance a targeted therapeutic approach aimed at changing the course of mCALR-driven blood cancers, an area where existing treatments remain largely focused on disease management rather than eliminating the underlying driver.

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.